Myriad Genetics, Inc.
MYGN
$4.81
-$0.34-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 81.41% | -23.98% | -800.54% | 99.62% | -36.22% |
| Total Depreciation and Amortization | -14.86% | -19.23% | -6.62% | -8.28% | -1.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -87.18% | 0.00% | 1,144.53% | -250.41% | 2,066.67% |
| Change in Net Operating Assets | 93.39% | 393.15% | -1,073.91% | 41.26% | 41.40% |
| Cash from Operations | 60.61% | 2,914.29% | -623.08% | 12.37% | 112.07% |
| Capital Expenditure | -30.56% | 20.00% | 46.15% | 20.90% | 64.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 43.48% | -254.55% | -241.67% | -650.00% | -15.00% |
| Cash from Investing | -1.69% | -182.67% | -7.81% | -16.90% | 50.83% |
| Total Debt Issued | -100.00% | 525.00% | -100.00% | -33.33% | -50.00% |
| Total Debt Repaid | 101.56% | -199.00% | 99.50% | 65.72% | 52.12% |
| Issuance of Common Stock | -79.31% | -- | -10.00% | -- | -97.65% |
| Repurchase of Common Stock | 0.00% | 90.00% | 100.00% | 33.33% | 20.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,875.00% | -- | -- | -- | -300.00% |
| Cash from Financing | -490.48% | 1,912.90% | 8.33% | 254.55% | -98.28% |
| Foreign Exchange rate Adjustments | 114.29% | -100.00% | 185.71% | 112.50% | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -266.67% | 726.74% | -293.18% | 69.12% | -96.24% |